News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
PharmaGap Inc. Releases Pre-clinical Animal Efficacy Data For Lead Drug Compound For Oncology
January 26, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PharmaGap Inc. (TSX-V: GAP) ("PharmaGap" or "the Company"), today released the first animal efficacy data for its novel lead drug compound, PhGalpha1, a selective inhibitor of Protein Kinase C-alpha (PKC-alpha).
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
MORE ON THIS TOPIC
Insights
JPM26: As Capital Concentrates, VCs Scrutinize Founder Pedigree and CEO Fit in Early Biotech
January 15, 2026
·
2 min read
·
Jennifer Smith-Parker
Business
JPM26: Lilly Plots Path to Dominance as Obesity Market Enters a New Era
January 14, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Deals Roll at JPM26, Policy Front and Center, IPOs Are Back, FDA Stays Busy
January 14, 2026
·
2 min read
·
Heather McKenzie
Business
JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff
January 13, 2026
·
3 min read
·
Nick Paul Taylor
